Summary of RCUS Q2 2026 Earnings Call

1Key Financial Results and Metrics

Cash and Investments: $775 million as of June 30, 2026, down from $876 million at the end of Q1 2026.

GAAP Revenue: $41 million for Q2 2026, with a full-year expectation of $65 to $75 million, primarily driven by collaboration agreements.

R&D Expenses: $113 million for Q2, with expectations of a significant decrease in overall R&D spending in 2026 and 2027 due to the wind-down of certain programs.

G&A Expenses: $24 million for Q2, with total non-cash stock-based compensation at $15 million.

2Strategic Updates and Business Highlights

Casdatifan Development: The company is focusing on advancing casdatifan, a next-generation HIF-2-alpha inhibitor, with plans for a broad development program across various lines of therapy in clear cell RCC (renal cell carcinoma).

Phase III Trials: Enrollment for the PEAK-1 trial (casdatifan plus cabozantinib) is on track to complete by year-end 2026. A new Phase III trial (PEAK-20) is planned to start by the end of 2026.

Collaborations: New partnerships with BMS, Summit Therapeutics, and AVEO are aimed at exploring combinations of casdatifan with other therapies, enhancing its market position.

Immunology Portfolio: The company is advancing several immunology programs, including AB102, an oral MRGPRX2 antagonist, expected to enter clinical trials soon.

3Forward Guidance and Outlook

Market Opportunity: The total peak sales opportunity for casdatifan is estimated at $5 to $10 billion, driven by its potential to become the backbone of RCC treatment.

Cash Runway: Expected to last into at least the second half of 2028, providing sufficient resources to support ongoing development efforts.

Upcoming Data: Significant data readouts are anticipated in October 2026, which will provide insights into casdatifan's efficacy across various treatment lines.

4Bad News, Challenges, or Points of Concern

Collaboration Revenue Decline: Future operating results may reflect lower collaboration revenue due to reduced activity under the Gilead collaboration.

Competitive Pressures: The recent failure of Merck's LITESPARK-012 study has removed a competitor in the frontline setting, but ongoing competition remains a concern.

Clinical Risks: The company must navigate the complexities of clinical trial outcomes, particularly in demonstrating the superiority of casdatifan over existing therapies.

5Notable Q&A Insights

Data Expectations: Management emphasized the importance of demonstrating casdatifan's potential as the backbone of RCC treatment across all lines, with particular focus on safety and primary progression rates in upcoming data.

Prior TKI Exposure: There is confidence that prior TKI exposure will not negatively impact casdatifan's efficacy, contrasting with findings from other studies.

Response Rates: Management is cautious about providing specific ORR (overall response rate) data early, focusing instead on safety and primary progression metrics initially.

Market Comparisons: Future data presentations will include comparative analyses against other therapies, particularly highlighting the advantages of casdatifan in terms of durability and efficacy. This summary encapsulates the key points from the earnings call, providing a balanced view of the company's current status, strategic direction, and potential challenges ahead.